Abstract
AbstractThis invited Team Profile was created by the McClements and the Wen groups, Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney (Australia); and the Kaitu'u‐Lino/Hannan groups, Mercy Hospital for Women, the University of Melbourne (Australia). They recently published an article on the development and validation of the first‐in‐class point‐of‐care assay for preeclampsia diagnosis. This assay can detect and quantify the concentration of FKBPL and CD44 proteins in human plasma in 15 minutes with high sensitivity and specificity enabling timely diagnosis of early‐onset preeclampsia. “Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity”, S. M. Ghorbanpour, S. Wen, T.'u. J. Kaitu'u‐Lino, N. J. Hannan, D. Jin, L. McClements,, Angew. Chem. Int. Ed. Engl. 2023, 62, e202301193.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
